Kynexis
Kynexis is advancing precision therapeutics for brain diseases by taking a biomarker-based approach to advance a potential first-in-class treatment for cognitive impairment associated with schizophrenia (CIAS). By harnessing large data to identify and stratify patients based on the underlying causal human. biology of the disease, Kynexis is targeting KAT-II, a key enzyme in the kynurenine pathway. The company’s lead candidate, KYN-5356, is a first-in-class small molecule that is potent and highly selective for KAT-II.
7-day free trial · no credit card
Verified contacts
8
available on Kipplo
LinkedIn employees
19
11 to 50 range
Open roles
—
no listings
Distinct roles
3
indexed titles
Tech stack
1
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 8 verified contacts at Kynexis
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
8 contacts with verified email or phone · masked until revealed.
- LC
Lauren Cortellessa
Director of Operations · Operations
EmailPhone - AH
Allison Hughes
, () · Other
EmailPhone - MS
Misty Sturges
Clinical Site Relationship Manager · Other
EmailPhone
Showing 3 of 8 verified contacts
Top roles at Kynexis
3 distinct titles indexed · top 3 shown.
- 1, ()
- 1clinical site relationship manager
- 1director of operations
Sign up to unlock all 8 contacts at Kynexis
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 8 verified contacts at Kynexis
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.